Lactic Acid From Fermented Foods Blocked Food Allergy Responses in Mice

A compound that gives yogurt, sauerkraut, and sourdough their tang may have a previously unrecognized role in calming food allergies. Researchers led by Ruofan Xie, publishing in the Journal of Agricultural and Food Chemistry, report that dietary lactic acid (LA) significantly reduced allergic responses in a mouse model of food allergy, working through a mechanism that touches dendritic cells, IgE production, and the physical integrity of the intestinal wall. This is early, investigational research in mice, and the road to human applications is long, but the mechanistic picture the study draws is detailed enough to be worth understanding.

Lactic Acid Slashed IgE Levels and Mast Cell Activation

The central finding is quantitative and striking. Mice sensitized to ovalbumin (OVA), a standard protein used to model food allergy, were treated with LA at three concentrations: 50, 100, and 200 mM. Across all three doses, serum OVA-specific IgE, the antibody class that drives classical allergic hypersensitivity, fell significantly (P < 0.0001). The effect on mast cell protease MCPT-1, a proxy for mast cell activation during an allergic reaction, was even more pronounced: LA reduced mMCPT-1 levels by 63.6%, 77.6%, and 90.5% respectively, all with P < 0.0001. Allergic diarrhea, one of the clearest behavioral readouts of food allergy in mice, was significantly attenuated at medium and high doses. LA also reversed the hypothermia that accompanies severe allergic reactions, with body temperature recovering toward normal in treated animals. Taken together, the findings suggest LA was suppressing type 2 immunity, the immune arm that drives IgE production and allergic inflammation, in a dose-dependent way.

Beyond antibodies, LA reduced levels of the cytokines IL-4, IL-5, and IL-13 in mesenteric lymph nodes upon OVA restimulation, all with P < 0.0001. These three interleukins are the signature effectors of Th2-driven allergy, so their coordinated reduction points to a change upstream in how the immune system is interpreting the allergen, not just a downstream suppression of symptoms.

Why Intestinal Barrier Repair Could Be the Pivotal Mechanism

Food allergies affect millions of people globally, and childhood food allergy is associated with substantially reduced quality of life, including elevated anxiety and impaired psychosocial functioning. One reason interventions remain limited is that the condition involves multiple interacting systems: the gut barrier, the innate immune system, and adaptive T and B cell responses. A compound that addresses more than one of these simultaneously is theoretically more powerful than a single-target drug.

The study found that LA repaired intestinal barrier proteins in a dose-dependent fashion. Occludin-1, a tight junction protein that holds gut epithelial cells together, increased by 60.9%, 119.8%, and 156.1% at low, medium, and high doses respectively. Claudin-2, a protein associated with leaky, permeable gut junctions, fell by 69.4%, 60.9%, and 46.5% across the same doses. A more intact gut barrier means less allergen crossing into the lamina propria, where it can trigger immune activation. This dual action on tight junction proteins gives LA a plausible structural role alongside its immune effects.

How the OVA Mouse Model Was Used to Probe Dendritic Cell Function

The team used an ovalbumin-induced allergic mouse model, a workhorse of food allergy research. Mouse models are well established in this field because mouse and human immune systems share enough architectural similarity to accelerate mechanistic hypothesis testing. The approach here went beyond measuring systemic antibody levels. The researchers specifically investigated what LA does to bone-marrow-derived dendritic cells (DCs), the sentinels of the innate immune system that capture antigens and decide whether to trigger tolerance or alarm.

The study found that LA suppressed OVA uptake and presentation by DCs. In practical terms, LA appeared to reprogramme these cells so they were less likely to process and display the allergen to T cells in a way that kicks off an allergic cascade. This is a mechanistically important distinction: LA was not simply calming inflammation after it started; it was intervening at the point where the immune system decides how to categorize the allergen in the first place.

Research into lactic acid bacteria shows they can rebalance Th1/Th2 ratios and increase regulatory T cells in allergic contexts, and this study's DC findings fit within that broader picture of fermentation-derived compounds influencing immune polarization.

Caveats That Matter Before Extrapolating to People

Several limitations deserve explicit attention. First, this is mouse data. Mouse models of food allergy simulate human disease in important ways, but they also have real limitations, including differences in sensitization routes and the incomplete translation of specific immune mechanisms across species. OVA is a useful experimental allergen, but it is not peanut, milk, or wheat, which are the allergens causing the most severe reactions in humans.

Second, the study does not establish what dose of lactic acid would be needed in a human, how it would be delivered reliably, or whether the concentrations tested here are achievable through normal dietary intake of fermented foods. A separate line of research noted in the background adds an interesting wrinkle: reducing endogenous lactate production also appears to ameliorate food allergy in some models, which suggests the biology of lactic acid and lactate in immune regulation is more complex than a simple more-is-better story. These apparent contradictions will need resolution before any clinical framework can be built.

What Researchers Would Need to Do Next

The mechanistic detail in this study, specifically the focus on DC reprogramming and tight junction protein expression, gives researchers defined targets for follow-up. The next logical steps would include testing whether the effect holds in models using clinically relevant allergens like peanut proteins, determining whether the DC effects observed in bone-marrow-derived cells translate to intestinal DCs in vivo, and exploring whether existing fermented food consumption correlates with altered food allergy risk in humans.

The broader landscape of emerging food allergy treatments includes allergen immunotherapy, biologics targeting IgE, and microbiome-modulating strategies. A food-derived compound that appears to work upstream of allergen sensitization, at the DC level, could eventually complement these approaches rather than replace them. That is speculative for now, but the mechanistic specificity of the Xie et al. findings at least makes it a coherent hypothesis worth testing in future, more translationally focused work.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• This study was conducted entirely in mice; results may not translate to humans.
• No funding source was disclosed, so independent replication has not been confirmed.
• The study notes that reducing endogenous lactate production also ameliorates food allergy in other models, suggesting the role of lactic acid is more complex than a simple beneficial effect.

Preclinical mouse study using an ovalbumin-induced allergy model. Results demonstrate dose-dependent attenuation of allergic markers with a proposed step-by-step mechanism through dendritic cell reprogramming, but findings are limited to an animal model and have not yet been replicated in human populations. The study's own background acknowledges contradictory evidence regarding lactate's role in allergy, which warrants caution in interpretation.

References

1. Ruofan Xie, Fan Yang, Yong Wu, et al. (2026). Dietary Lactic Acid Attenuates Ovalbumin-Induced Food Allergy in Mice via Orchestrating Dendritic Cell and T Cell Immune Tolerance. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/acs.jafc.6c04382
2. Selene Valero-Moreno, Rocío Torres-Llanos, Marián Pérez-Marín (2024). Impact of Childhood Food Allergy on Quality of Life: A Systematic Review. Applied Sciences. https://doi.org/10.3390/app142310989
3. Johanna M. Smeekens, Michael D. Kulis (2021). Mouse Models of Food Allergy in the Pursuit of Novel Treatment Modalities. Frontiers in Allergy. https://doi.org/10.3389/falgy.2021.810067
4. Chunqing Ai, Na Ma, Qiuxiang Zhang, et al. (2016). Immunomodulatory Effects of Different Lactic Acid Bacteria on Allergic Response and Its Relationship with In Vitro Properties. PLOS ONE. https://doi.org/10.1371/journal.pone.0164697
5. Avishay Edri, Avishai Shemesh, Muhammed Iraqi, et al. (2018). The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.01428
6. David W Hwang, Cathryn R Nagler, Christina E Ciaccio (2022). New and emerging concepts and therapies for the treatment of food allergy. Immunotherapy Advances. https://doi.org/10.1093/immadv/ltac006